Sponsored Content

The following article is content provided by our sponsor Novartis Gene Therapies, Inc. The views and opinions expressed in the content below are not the views and opinions of HCP SMA News Today or its parent company, BioNews Inc.   ZOLGENSMA® (onasemnogene abeparvovec-xioi) is a gene therapy for the treatment…

The following article is content provided by our sponsor Novartis Gene Therapies, Inc. The views and opinions expressed in the content below are not the views and opinions of HCP SMA News Today or its parent company. BioNews, Inc.     ZOLGENSMA® (onasemnogene abeparvovec-xioi) is a gene therapy for…

Treatment for spinal muscular atrophy (SMA) has undergone a major paradigm shift. Previously, management focused on supportive care; today, with disease-modifying treatment options, patients demonstrate significant improvement over the natural history.1,2 Without treatment, SMA Type 1 has historically been a leading genetic cause of infant death, with a life…

Novartis Gene Therapies – For spinal muscular atrophy (SMA), the importance of presymptomatic treatment cannot be understated. Children who are identified quickly through newborn screening and genetic testing and are treated before the onset of signs are more likely to have better treatment outcomes than patients who are symptomatic when…

Novartis Gene Therapies—ZOLGENSMA® (onasemnogene abeparvovec-xioi) suspension for intravenous infusion is a gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA). ZOLGENSMA has a Boxed Warning for Acute Serious Liver Injury and Acute Liver Failure. Please continue reading below for…